News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AlloCure Inc. Begins Phase 2 Clinical Trial in Acute Kidney Injury


9/4/2012 10:01:06 AM

BURLINGTON, Mass.--(BUSINESS WIRE)--AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company’s mesenchymal stem cell therapy, as a potential treatment for acute kidney injury (AKI). The randomized, double-blind, placebo-controlled, multi-center trial, designated ACT-AKI (AC607 Trial in Acute Kidney Injury) (NCT01602328), will enroll 200 cardiac surgery subjects at leading tertiary care centers in the United States.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES